Cullinan Oncology LLC (CGEM) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063
Cancer, Antibodies, Therapies
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Web URL: https://www.cullinanoncology.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
CGEM Stock Overview
Market Cap in USD | 1,170m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2021-01-08 |
CGEM Stock Ratings
Growth 5y | -1.29 |
Fundamental | -73.4 |
Dividend | - |
Rel. Performance vs Sector | 9.59 |
Analysts | 4.78/5 |
Fair Price Momentum | 32.58 USD |
Fair Price DCF | - |
CGEM Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
CGEM Growth Ratios
Growth 12m | 188.94% |
Growth Correlation 12m | 30% |
Growth Correlation 3m | 23% |
CAGR 5y | -3.67% |
CAGR/Mean DD 5y | -0.06 |
Sharpe Ratio 12m | 2.69 |
Alpha vs SP500 12m | 152.21 |
Beta vs SP500 5y weekly | 1.30 |
ValueRay RSI | 70.04 |
Volatility GJR Garch 1y | 106.05% |
Price / SMA 50 | 34.39% |
Price / SMA 200 | 100.15% |
Current Volume | 641.5k |
Average Volume 20d | 1296k |
External Links for CGEM Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of CGEM stocks?
As of May 16, 2024, the stock is trading at USD 26.38 with a total of 641,499 shares traded.
Over the past week, the price has changed by -10.12%, over one month by +59.40%, over three months by +48.96% and over the past year by +165.39%.
As of May 16, 2024, the stock is trading at USD 26.38 with a total of 641,499 shares traded.
Over the past week, the price has changed by -10.12%, over one month by +59.40%, over three months by +48.96% and over the past year by +165.39%.
What is the forecast for CGEM stock price target?
According to ValueRays Forecast Model, CGEM Cullinan Oncology LLC will be worth about 36.6 in May 2025. The stock is currently trading at 26.38. This means that the stock has a potential upside of +38.74%.
According to ValueRays Forecast Model, CGEM Cullinan Oncology LLC will be worth about 36.6 in May 2025. The stock is currently trading at 26.38. This means that the stock has a potential upside of +38.74%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 33.1 | 25.6 |
Analysts Target Price | 24.6 | -6.75 |
ValueRay Target Price | 36.6 | 38.7 |